Catalog No.
RHK25503
Species reactivity
Human
Host species
Mouse
Isotype
IgG2a, kappa
Clonality
Monoclonal
Target
Transthyretin, Prealbumin, TBPA, TTR, PALB, ATTR, Transthyretin amyloidosis, mis-TTR
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Applications
ELISA, Neutralization, SPR, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
6C1
Current and emerging treatment options for transthyretin amyloid cardiomyopathy., PMID:40425273
Current Landscape of Therapies for Transthyretin Amyloid Cardiomyopathy., PMID:40335224
A scientometric study on research characteristics and trends of amyloidosis involving the oral cavity., PMID:40224046
Diagnosis of hereditary transthyretin amyloidosis in patients with suspected chronic inflammatory demyelinating polyneuropathy unresponsive to intravenous immunoglobulins: results of a retrospective study., PMID:40025610
Transthyretin Cardiac Amyloidosis: Current and Emerging Therapies., PMID:39841315
New therapies to treat cardiac amyloidosis., PMID:39819772
Advancing treatments for transthyretin amyloid cardiomyopathy: Innovations in RNA silencing, gene editing, TTR stabilization, and degradation., PMID:39775625
Disease-modifying therapies for amyloid transthyretin cardiomyopathy: Current and emerging medications., PMID:39714070
Pathogenesis, manifestations, diagnosis, and management of CNS complications in hereditary ATTR amyloidosis., PMID:39627935
Transthyretin Cardiac Amyloidosis in Australia and New Zealand-A Multi-Site Snapshot for 2022., PMID:39592278
Optimizing drug therapies in cardiac amyloidosis., PMID:39586360
PRX004 in variant amyloid transthyretin (ATTRv) amyloidosis: results of a phase 1, open-label, dose-escalation study., PMID:39472768
Prediction of Cardiac ATTR Depletion by NI006 (ALXN2220) Using Mechanistic PK/PD Modeling., PMID:39410666
Hereditary Transthyretin Amyloidosis Polyneuropathy., PMID:39406377
Structural Basis for Monoclonal Antibody Therapy for Transthyretin Amyloidosis., PMID:39338387
Anti-PEG antibodies associated with reduced therapeutic effect of patisiran in patients with hereditary transthyretin amyloidosis., PMID:39126640
[Clinical case of generalized amyloidosis (ATTR-amyloidosis) with a progressive course of chronic heart failure. Case report]., PMID:39106513
Recent advances in the diagnostic methods and therapeutic strategies of transthyretin cardiac amyloidosis., PMID:39086890
Antithrombotic properties of Tafamidis: An additional protective effect for transthyretin amyloid cardiomyopathy patients., PMID:39029855
Amyloid Neuropathy: From Pathophysiology to Treatment in Light-Chain Amyloidosis and Hereditary Transthyretin Amyloidosis., PMID:38923548
Specific Therapy in Transthyretin Amyloid Cardiomyopathy: Future Perspectives Beyond Tafamidis., PMID:38844305
Identification of isoaspartate-modified transthyretin as potential target for selective immunotherapy of transthyretin amyloidosis., PMID:38801321
Treatment of transthyretin cardiac amyloidosis., PMID:38652263
[Modern Perspectives on Peripheral Neuropathology]., PMID:38589281
Detection of TTR Amyloid in the Conjunctiva Using a Novel Fluorescent Ocular Tracer., PMID:38359019
Breakthrough advances enhancing care in ATTR amyloid cardiomyopathy., PMID:38184468
Epidemiological study of the subtype frequency of systemic amyloidosis listed in the Annual of the Pathological Autopsy Cases in Japan., PMID:38088470
Strong positive light chain immunostaining in a patient with transthyretin amyloidosis., PMID:37551718
RNAi therapeutics for diseases involving protein aggregation: fazirsiran for alpha-1 antitrypsin deficiency-associated liver disease., PMID:37470509
Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid., PMID:37212440
Treatment of amyloidosis: present and future., PMID:37091663
Monoclonal antibodies and amyloid removal as a therapeutic strategy for cardiac amyloidosis., PMID:37091656
Statin-Induced Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase (Anti-HMGCR) Myopathy., PMID:36843759
Monoclonal Gammopathy of Undetermined Significance in Patients With Transthyretin Amyloidosis (ATTR): Analysis Using the iStopMM Criteria., PMID:36621346
Antisense Oligonucleotide Therapy for the Nervous System: From Bench to Bedside with Emphasis on Pediatric Neurology., PMID:36365206
Early transverse tubule involvement in cardiomyocytes in hereditary transthyretin amyloidosis: a possible cause of cardiac events., PMID:35872346
Clinical advances of RNA therapeutics for treatment of neurological and neuromuscular diseases., PMID:35482908
Cardiac Amyloidosis Treatment., PMID:35414852
Enhanced quantitative method for the diagnosis of grade 1 cardiac amyloidosis in 99mTc-DPD scintigraphy., PMID:35110594
Developing Therapy for Transthyretin Amyloidosis., PMID:35077703
Yet another amyloidosis., PMID:34965957
Pathological review of cardiac amyloidosis using autopsy cases in a single Japanese institution., PMID:34653913
The Ultrastructure of Tissue Damage by Amyloid Fibrils., PMID:34361762
Progress and challenges in the treatment of cardiac amyloidosis: a review of the literature., PMID:34089308
Potential Cardiac Amyloid PET/CT Imaging Targets for Differentiating Immunoglobulin Light Chain From Transthyretin Amyloidosis., PMID:34081210
A human antibody selective for transthyretin amyloid removes cardiac amyloid through phagocytic immune cells., PMID:34035264
Pathophysiology and Therapeutic Approaches to Cardiac Amyloidosis., PMID:33983835
Transthyretin Amyloid Cardiomyopathy-Current and Future Therapies., PMID:33685242
A case of wild-type transthyretin cardiac amyloidosis with rheumatoid arthritis., PMID:33314981
Understanding and recognizing cardiac amyloidosis., PMID:32941304
For research use only. Not for human or drug use.
